Associated Papers
Targeting oncogenic K-RAS mutants with small-molecule degrader XMU-MP-9 through NEDD4-1.
Zeng T et al.
Acta Pharmaceutica Sinica. B, 2026
K128 ubiquitination constrains RAS activity by expanding its binding interface with GAP proteins.
Magits W et al.
The Embo Journal, 2024
38858602 (PubMed )
Supplement: 44318_2024_146_MOESM1_ESM.pdf
Delineating the RAS Conformational Landscape.
Parker MI et al.
Cancer Research, 2022
35536216 (PubMed )
Supplement: can-22-0804_supplementary_datasets_s1-s4_suppsds1-sds4.xlsx › Supplementary_Dataset_S1
Structural bioinformatics enhances mechanistic interpretation of genomic variation, demonstrated through the analyses of 935 distinct RAS family mutations.
Tripathi S et al.
Bioinformatics (oxford, England), 2021
33226070 (PubMed )
Supplement: btaa972_supplementary_data.zip › RAS_Manuscript_RMarkdown.tar.gz › RAS_Manuscript1.Revised › RAS_Variants_Scores.xlsx › Sheet1
Identification of pathogenic missense mutations using protein stability predictors.
Gerasimavicius L et al.
Scientific Reports, 2020
32958805 (PubMed )
Supplement: 41598_2020_72404_MOESM2_ESM.xlsx › gnomAD
Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction.
Hillig RC et al.
Proceedings of the National Academy of Sciences of the United States of America, 2019
30683722 (PubMed )
Supplement: pnas.1812963116.sapp.pdf
Genetic diagnosis of high-penetrance susceptibility for colorectal cancer (CRC) is achievable for a high proportion of familial CRC by exome sequencing.
Chubb D et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2015
Select a paper to view details